Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 4367-4372

  Lin, Tao ^a   Song, Chun ^a   Chuo, Dong yu ^a   Zhang, Hao ^a   Zhao, Jian ^a  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Colorectal cancer; Cytokine induced killer cell; Dendritic cells; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE PLUS OXALIPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; CANCER VACCINE;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADOPTIVE IMMUNOTHERAPY; AGED; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG THERAPY; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADULT; AGED; CANCER VACCINES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84945151804     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3957-2     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IGH. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137:305–10.
3. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, et al. Developments in clinical cell therapy. Cytotherapy. 2010;12:425–8.
4. Okada N. Cell delivery system: a novel strategy to improve the efficacy of cancer immunotherapy by manipulation of immune cell trafficking and biodistribution. Biol Pharm Bull. 2005;28:1543–50.
5. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother. 1998;47:221–6.
6. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704–19.
7. Shapira S, Lisiansky V, Arber N, Kraus S. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin Investig Drugs. 2010;19:S67–77.
8. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117.
9. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: Implications for their infusion across major HLA barriers. Int Immunol. 2008;20:841–8.
10. Ling W, Fan J, Ma Y, Ma Y, Wang H. Capecitabine-based chemotherapy for metastatic colorectal cancer. J Cancer Res Clin Oncol. 2011;137:927–38.
11. Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer a population-based analysis. Cancer. 2012;118:4309–20.
12. Zhu Y, Zhang H, Li Y, Bai J, Liu L, Liu Y, et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother. 2013;62:1629–35.
13. Niu JX, Ren YJ, Zhang TY, Yang XJ, Zhu W, Zhu H, et al. Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer. Biomed Res Int. 2014;2014:214727.
14. Zhong RB, Teng JJ, Han BH, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60:1497–502.
15. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy. 2010;2:37–56.
16. Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy. 2010;2:57–68.
17. Li X-D, Xu B, Wu J, Ji M, Xu B-H, Jiang J-T, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol. 2012;14:102–8.
18. Schmidt-Wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999;81:1009–16.
19. Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett. 2013;6:537–41.
20. Liu Y, Zhang W, Zhang B, Yin X, Pang Y. Dc vaccine therapy combined concurrently with oral capecitabine in metastatic colorectal cancer patients. Hepatogastroenterology. 2013;60:23–7.
21. Zhang JY, Zhu LJ, Zhang Q, He X, Yin YM, Gu YH, et al. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. Biomed Pharmacother. 2014;68:715–20.
22. Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR, et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res. 2007;13:5455–62.
23. Hui KM. Cik cells - current status, clinical perspectives and future prospects - the good news. Expert Opin Biol Ther. 2012;12:659–61.
24. Lu PH, Negrin RS. A novel population of expanded human cd3 + cd56+ cells derived from t-cells with potent in-vivo antitumor-activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–96.
25. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev. 1997;157:231–40.
26. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388–97.
27. Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001;24:502–10.
28. Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF, et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy. 2012;14:483–93.
29. Lu W, Li Y-H, He X-F, Chen Y, Zeng Q-L, Qiu Y-R. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on t cell subsets in patients with hepatocellular carcinoma. Di Yi Jun Yi Da Xue Xue Bao. 2002;22:524–6.
30. Zhang Y-S, Yuan F-J, Jia G-F, Zhang J-F, Hu L-Y, Huang L, et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol. 2005;11:3339–45.
31. Zhang G, Zhao H, Wu J, Li J, Xiang Y, Wang G, et al. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol. 2014;21:396–405.
32. Introna M, Golay J, Rambaldi A. Cytokine induced killer (CIK) cells for the treatment of haematological neoplasms. Immunol Lett. 2013;155:27–30.
33. Chung MJ, Park JY, Bang S, Park SW, Song SY. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother. 2014;63:939–46.